

Published in final edited form as:

Nature. 2013 September 19; 501(7467): 426–429. doi:10.1038/nature12447.

Bacterial colonization factors control specificity and stability of the gut microbiota

S. Melanie Lee¹, Gregory P. Donaldson¹, Zbigniew Mikulski², Silva Boyajian¹, Klaus Ley², and Sarkis K. Mazmanian^{1,*}

¹Division of Biology & Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA

²Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA

Abstract

Mammals harbor a complex gut microbiome, comprised of bacteria that confer immunologic, metabolic and neurologic benefits¹. Despite advances in sequence-based microbial profiling and myriad studies defining microbiome composition during health and disease, little is known about the molecular processes employed by symbiotic bacteria to stably colonize the gastrointestinal (GI) tract. We sought to define how mammals assemble and maintain the *Bacteroides*, one of the most numerically prominent genera of the human microbiome. While the gut normally contains hundreds of bacterial species^{2,3}, we surprisingly find that germ-free mice mono-associated with a single *Bacteroides* are resistant to colonization by the same, but not different, species. To identify bacterial mechanisms for species-specific saturable colonization, we devised an *in vivo* genetic screen and discovered a unique class of Polysaccharide Utilization Loci (PUL) that are conserved among intestinal *Bacteroides*. We named this genetic locus the commensal colonization factors (*ccf*). Deletion of the *ccf* genes in the model symbiont, *Bacteroides fragilis*, results in colonization defects in mice and reduced horizontal transmission. The *ccf* genes of *B. fragilis* are up-regulated during gut colonization, preferentially at the colonic surface. When we visualize microbial biogeography within the colon, *B. fragilis* penetrates the colonic mucus and resides deep within crypt channels, while *ccf* mutants are defective in crypt association. Remarkably, the CCF system is required for *B. fragilis* colonization following microbiome disruption with *Citrobacter rodentium* infection or antibiotic treatment, suggesting the niche within colonic crypts represents a reservoir for bacteria to maintain long-term colonization. These findings reveal that intestinal *Bacteroides* have evolved species-specific physical interactions with the host that mediate stable and resilient gut colonization, and the CCF system represents a novel molecular mechanism for symbiosis.

International microbiome sequencing initiatives are revealing detailed inventories of diverse bacterial communities across various body sites, diets and human populations²⁻⁴. Complex ecosystems have been forged by co-adaptation over millennia between animals and microbes to create stable and specific microbiomes^{5,6}, suggesting the evolution of molecular

Correspondence and requests for materials should be addressed to S.K.M. sarkis@caltech.edu.

Reprints and permissions information is available at www.nature.com/reprints.

Author Contributions. S.M.L. and S.K.M. conceived the project. S.M.L. performed most of the experiments; G.P.D., Z.M. and S.B. contributed data. S.M.L., G.P.D., Z.M., K.L. and S.K.M. interpreted the data. K.L. and S.K.M. secured funding. S.M.L. and S.K.M. wrote the manuscript, G.P.D., Z.M. and K.L. edited the manuscript. G.P.D. and Z.M. contributed equally to the work.

The authors declare no competing financial interests.

Readers are welcome to comment on the online version of this article at www.nature.com/nature.

mechanisms that establish and maintain symbiotic microbial colonization. *Bacteroidetes* is one of the most numerically abundant Gram-negative phyla in the mammalian GI tract⁷. Studies in the genus *Bacteroides* have revealed species that induce glycosylation of the intestinal epithelium⁸, produce glycoside hydrolases that digest carbohydrates for host nutrient utilization⁹, direct host immune maturation¹⁰ and protect animals from inflammation in experimental models of IBD and multiple sclerosis¹¹⁻¹³. To explore the dynamics of microbiome assembly, we sequentially introduced *Bacteroides* species to germ-free mice and monitored colonization via colony-forming units (CFU) in feces. Animals are readily colonized with *Bacteroides fragilis* followed by *Bacteroides thetaiotaomicron* (Fig. 1a) or *Bacteroides vulgatus* (Fig. 1b), and altering the sequence of microbial exposure does not affect results (Supplementary Fig. 1a). Remarkably however, animals colonized with *B. fragilis* and then exposed to the same species (marked by an antibiotic resistance gene) are resistant to super-colonization and clear the challenging strain (Fig. 1c). This novel observation of ‘colonization resistance’ by the same species is conserved in three other *Bacteroides* (Supplementary Fig. 1b-d), regardless of the antibiotic resistance markers used (Supplementary Fig. 1e), but not in *Escherichia coli* (Supplementary Fig. 1f). As conventional mice typically harbor 10¹¹-10¹² CFU per gram of cecal content¹⁴ (100-fold greater than *Bacteroides* in mono-association), there appears to be no shortage of space or nutrients under these conditions, using a nutrient rich standard diet. We thus hypothesized that individual *Bacteroides* species colonize the gut by saturating a limited and unique niche. Indeed, treatment of *B. fragilis* mono-associated mice with erythromycin to displace the existing strain permits colonization by an erythromycin-resistant challenge strain (Fig. 1d). These data suggest that *Bacteroides* colonize the gut in a species-specific and saturable manner.

We developed a functional *in vivo* screen to identify genetic factor(s) from *B. fragilis* that are sufficient to mediate species-specific colonization. Mice were mono-associated with *B. vulgatus*, then challenged with a library of *B. vulgatus* clones that each contained a fragment of *B. fragilis* genomic DNA (schematic in Supplementary Fig. 2a). We reasoned that only those clones containing genes that conferred stable gut colonization by *B. fragilis* would persist, with the remainder being cleared. We screened 2,100 clones each containing 9-10 kilobases of DNA, providing a 3.8-fold coverage of the *B. fragilis* genome and 98% probability that a given DNA sequence is present in the library (Supplementary Eq. 1). Remarkably, 30 days after orally gavaging the library into animals, only two clones sustained colonization. The inserts from both clones mapped to the same locus on the *B. fragilis* genome, BF3579-BF3583 (Supplementary Fig. 2b).

Based on predicted protein sequences, BF3583 and BF3582 is a sigma (σ) factor/anti- σ factor gene pair. BF3581 is a member of the SusC family of outer membrane proteins. BF3580 is a homolog of SusD, a lipoprotein often paired with SusC. These Sus-like systems have been shown to bind and import a range of oligosaccharide molecules¹⁵⁻¹⁸. BF3579 encodes a putative chitinase, suggesting a possible polysaccharide substrate for this system¹⁹ (Fig. 1e). Comparative genomic analysis using the Integrated Microbial Genomes database (<http://img.jgi.doe.gov/cgi-bin/w/main.cgi>) reveals conservation of similar clusters of genes among sequenced intestinal *Bacteroides* species (Supplementary Fig. 3). Sus-like systems are numerous in *Bacteroides* within polysaccharide utilization loci (PULs), which are gene cassettes used to harvest dietary sugars and/or forage host glycans during nutrient deprivation^{15,20,21}. As PULs have previously not been implicated in saturable niche colonization, the locus we have identified encodes a unique pathway in *Bacteroides* for species-specific gut association; we named the genes *ccfA-E*, for commensal colonization factors (Fig. 1e). Furthermore, as deletion of the most closely related genes from *B. fragilis* (BF Δ 0227-0229; Supplementary Fig. 3) do not impact colonization dynamics

(Supplementary Fig. 4), we suggest that the CCF system represents a functionally unique subset of PULs that evolved to promote long-term symbiosis.

To test if the putative structural genes (*ccfC-E*) are required for gut colonization, we generated in-frame deletion mutants of *B. fragilis*; $\Delta ccfC$, $\Delta ccfD$ and $\Delta ccfE$. All strains exhibit normal morphology on solid agar medium and unimpaired growth in laboratory culture (data not shown). As previously shown, animals mono-colonized with WT *B. fragilis* completely clear the WT challenge strain after 30 days (Fig. 1f; 1st bars). However, animals mono-associated with $\Delta ccfC$ or $\Delta ccfD$ are permissive to colonization by WT bacteria (Fig. 1f; 2nd and 3rd bars), unlike the *ccfE* mutant (Fig. 1f; 4th bars). A deletion mutant in all three genes (*B. fragilis* ΔCCF) also allows WT *B. fragilis* to colonize (Fig. 1f; 5th bars). Trans-complementation of the *B. fragilis* ΔCCF strain with *ccfA-E* restores colonization resistance (Fig. 1f; 6th bars). Similarly, a mutant in the *B. vulgatus ccfC-E* orthologs ($\Delta BVU0946$ - $BVU0948$) also permits WT *B. vulgatus* to colonize (Fig. 1g), demonstrating conservation in *Bacteroides* species. When we tested horizontal transmission of bacteria between WT *B. fragilis* and *B. fragilis* ΔCCF mono-associated mice, only WT bacteria cross-colonized (Fig. 1h). Thus, the CCF system is involved in colonization resistance by *Bacteroides*.

Building on the previous discovery that a population of *B. fragilis* associates with mucosal tissues²², we show that *ccfB-E* are preferentially expressed by bacteria in contact with the colon, with lower levels in cecal content and feces (Fig. 2a). There is virtually no expression in laboratory culture. Thus, *in vivo* expression of *ccf* in gut tissue may be critical for colonization. Indeed, in contrast to laboratory grown bacteria (see Fig. 1c), sustained colonization is conferred to bacteria recovered directly from animals (Supplementary Fig. 5). To examine regulation of gene expression, we deleted the σ factor *ccfA*, which led to highly reduced expression of all five genes during animal colonization (Supplementary Fig. 6a). Accordingly, germ-free mice mono-colonized with *B. fragilis* $\Delta ccfA$ mutant are permissive of super-colonization by WT *B. fragilis*, demonstrating a functional defect in the saturable niche occupancy (Supplementary Fig. 6b). Based on the tissue-associated expression pattern, we tested if the CCF system promotes bacterial localization to mucosal tissue. Mice were mono-associated with either the WT or the *ccf* deletion strain, and both groups were subsequently challenged with WT *B. fragilis*. 24 hours after challenge, we observe the same numbers for challenge strains in feces of both groups (Fig. 2b; 1st and 2nd bars, and Supplementary Fig. 7a, b). In contrast, *ccf* mutant-associated animals show higher levels of challenge strain in colon tissue, suggesting a colonization defect by the mutant strain specifically at the mucosal surface (Fig. 2b; 3rd and 4th bars, and Supplementary Fig. 7a, b). Therefore, CCF-mediated colonization fitness appears to involve physical association with the gut.

Recent studies have revealed microbial communities that colonize intestinal crypts of conventional mice in the absence of disease²³ and we have shown that *B. fragilis* occupies the colonic crypts of mono-associated mice²². Discovering a role for *ccf* genes near mucosal tissue led us to explore the intriguing hypothesis that the CCF system mediates crypt occupancy. We mono-colonized mice with *B. fragilis* and visualized bacterial localization in colon tissue by whole-mount confocal microscopy. Indeed, WT *B. fragilis* co-localize with crypts from the ascending colon, appearing to be located in the center of crypt opening. Remarkably, *B. fragilis* ΔCCF mono-associated mice display virtually no crypt occupancy (Fig. 2c and Supplementary Fig. 8). Colon cross-section imaging also reveals that only WT bacteria are crypt associated (Supplementary Fig. 9). Two-photon imaging of colon explants clearly demonstrates presence of WT *B. fragilis* on the surface of the epithelium and inside the crypt. While both WT and mutant strains of *B. fragilis* associate with the surface of the epithelium, only WT bacteria are able to penetrate deep into the colonic crypts of mice (Fig. 2d and Supplementary video 1). Measuring the distance from the surface of the epithelium

to bacterial signals in a survey of crypts reveals significantly greater tissue penetration by WT bacteria (Fig. 2e). Collectively, these data reveal that the CCF system allows *B. fragilis* to reside in a specific niche within crypts during steady-state colonization.

We next investigated the effects of the CCF system in the context of a complex microbiota. Wild-type *Bacteroides* species do not readily colonize most strains of specific pathogen-free (SPF) mice, namely BALB/c, Swiss Webster and C57BL/6, despite oral administration of high inoculums (Supplementary Fig. 10a, c and data not shown). Furthermore, transfer of an SPF microbiota to mono-colonized mice leads to clearance of WT *B. fragilis* (Supplementary Fig. 10b, d). To overcome this obstacle, we tested various additional genetic backgrounds and empirically determined that C57BL/6 Rag^{-/-} mice (which lack an adaptive immune system) and non-obese diabetic (NOD) mice can be stably colonized by *B. fragilis* with a single oral gavage. We introduced either WT or *ccf* mutant *B. fragilis* at equal inoculums into separate groups of animals, and measured colonization. Only WT *B. fragilis* stably colonizes SPF Rag^{-/-} mice, whereas *B. fragilis*ΔCCF establishes a significantly lower colonization in the gut (Fig. 3a). Co-inoculation of equal numbers of WT and *ccf* mutant bacteria into Rag^{-/-} mice also results in rapid clearance of the mutant strain from the gut (Fig. 3b), demonstrating a cell intrinsic defect that could not be complemented in *trans* by WT bacteria. NOD animals are also preferentially colonized by WT *B. fragilis* compared to *ccf* mutants in separate groups of animals (Fig. 3c) or in equal co-inoculation (Fig. 3d). These data show that deletion of the *ccf* genes compromises *B. fragilis* colonization of hosts with a complex microbiota.

During symbiosis with mammals, the microbiota may be confronted by rapid environmental changes with potentially adverse consequences to bacteria, such as enteric infections or antibiotic exposure. Gastroenteritis is commonly experienced by humans and is known to perturb the microbiota. To test if resilience of *B. fragilis* colonization is CCF-dependent, we used *Citrobacter rodentium* infection of mice to mimic human GI infection²⁴. Employing an antibiotic treatment protocol that does not sterilize the gut but promotes colonization of SPF mice by *Bacteroides*²⁵, we were able to simultaneously colonize mice with equivalent levels of WT and *ccf* mutant bacteria. Mice were subsequently infected orally with *C. rodentium*, and colonization of *B. fragilis* was monitored. WT bacteria decline in number at first, but return to maximal levels 3-4 weeks post infection (Fig. 3e). Importantly, the *B. fragilis*ΔCCF strain is completely cleared from the mouse gut following gastroenteritis (Fig. 3e), but not when animals are left uninfected (Supplementary Fig. 11a). Next, we challenged mice that were co-colonized with WT and *B. fragilis*ΔCCF with oral antibiotics and observe a colonization defect only in *ccf* mutant bacteria (Fig. 3f and Supplementary Fig. 11b). These results reveal that the CCF system establishes resilient colonization by gut *Bacteroides* following disruption of the microbiome. Finally, when SPF mice colonized with WT *B. fragilis* were given an antibiotic treatment that cleared fecal bacteria, crypt-associated microbial populations persisted (Supplementary Fig. 12), suggesting that symbiotic bacteria occupy a protected niche that creates a reservoir for stable gut colonization.

Co-evolution has bound microbes and man in an inextricable partnership, resulting in remarkable specificity and stability of the human microbiome^{2,3}. Our findings reveal a novel pathway required for persistent colonization of the mammalian gut by the *Bacteroides*. Homology to the Sus family of proteins suggests a role for CCF in uptake and utilization of glycans. Although certain Sus-containing PULs in *B. thetaiotaomicron* mediate foraging of host mucus¹⁵, their contributions to microbial colonization have been previously described only during nutrient deprivation conditions²⁰. Our discovery of CCF-dependent colonization in mice fed a nutrient rich diet suggests a new role whereby *Bacteroides* evolved specific Sus-like systems to utilize non-dietary glycans during homeostasis. Based on the findings that *ccf* genes are preferentially expressed in proximity to mucosal tissues and *B. fragilis*

associates with colonic crypts, we find it likely that host factors may promote expression of the CCF system. In support of this notion, N-Acetyl-D-lactosamine (LacNAc)—a component of host mucus—induces the *ccf* genes and its homologs in *B. fragilis* and *B. thetaiotaomicron*²⁰ (Supplementary Fig. 13). But since a closely related PUL (BF0227-31) responds to LacNAc but does not mediate saturable niche colonization (Supplementary Fig. 4), LacNAc alone may be an inducer but is not the substrate utilized by CCF systems. We propose that specific glycan structures within colonic crypts serve as nutrient sources for individual *Bacteroides* species, and that CCF systems provide a molecular mechanism for a hypothesis proposed decades ago, “that populations of most indigenous intestinal bacteria are controlled by substrate competition, i.e., that each species is more efficient than the rest in utilizing one or a few particular substrates and that the population level of that species is controlled by the concentration of these few limiting substrates”²⁶. Future work will aim to identify the precise glycan(s) for CCF systems from various *Bacteroides*. Finally, our data suggests that the *ccf* genes encode for a specific subset of PULs that evolved the novel activity of promoting stable and resilient colonization, and crypt-associated bacterial reservoirs may represent ‘founder’ cells that repopulate the gut following disruption of the microbiome by enteric infections or antibiotic exposure. Discovery of a molecular mechanism for colonization fitness by gut bacteria provides a glimpse into the evolutionary forces that have shaped the assembly and dynamics of the human microbiome.

Methods Summary

All germ-free mice were bred and housed in flexible film isolators until 8 weeks of age, then transferred to microisolator cages and maintained with autoclaved food, bedding and water supplemented with gentamicin and erythromycin. Mice were mono-associated with gentamicin and erythromycin resistant *Bacteroides* strains by single oral gavage. Colonization level was determined over time by stool serial dilution plating on selective agar media. For qRT-PCR, total RNA was extracted from laboratory bacterial culture, fecal and cecal content (ZR Soil/Fecal RNA MicroPrep™, Zymo Research) and colon tissues (Trizol, Invitrogen) from mono-associated animals, converted to first strand cDNA and analyzed by qPCR using Power SYBR Green PCR Master Mix (Applied Biosystems). For colon whole-mount imaging, tissues were harvested from germ-free or single strain mono-associated animals, fixed with 4% PFA and stained with a *B. fragilis* specific antibody, DAPI and phalloidin. The colon crypts were visualized by confocal microscopy and two-photon microscopy. SPF mice were colonized with *B. fragilis* and/or *B. fragilis*ΔCCF by single oral gavage and the colonization level was determined over time by stool DNA extraction (ZR Fecal DNA MiniPrep™, Zymo Research) and qPCR using strain specific primers.

Methods

Bacterial strains, plasmids and culture conditions

Bacterial strains and plasmids are described in Supplementary Table 1. *Bacteroides* strains were grown anaerobically at 37°C for two days in brain heart infusion broth supplemented with 5 µg/ml hemin and 0.5 µg/ml Vitamin K (BHIS), with gentamicin (200 µg/ml), erythromycin (5 µg/ml), chloramphenicol (10 µg/ml) and tetracycline (2 µg/ml) added where appropriate. *Escherichia coli* JM109 containing recombinant plasmids were grown in LB with ampicillin (100 µg/ml) or kanamycin (30 µg/ml). *Citrobacter rodentium* DBS100 strain was grown in LB at 37°C for 24 hours. For the induction of *susC/D* homologues, *B. fragilis* and *B. thetaiotaomicron* were grown in minimal medium (MM) with either glucose or N-acetyllactosamine as the sole carbon source as described previously²⁰.

Mice

8-10 week old male and female germ-free Swiss Webster mice were purchased from Taconic Farms (Germantown, NY) and bred in flexible film isolators. For gnotobiotic colonization experiments, germ-free mice were transferred to freshly autoclaved microisolator cages, fed *ad libitum* with a standard autoclaved chow diet and given autoclaved water supplemented with 10 µg/ml of erythromycin and 100 µg/ml of gentamicin. Male SPF (Specific Pathogen-Free) C57BL/6 mice and Swiss Webster mice were purchased from Taconic Farms. Male SPF NOD/ShiLtJ mice and Rag-/- C57BL/6 mice were purchased from the Jackson Laboratory. No randomization or blinding was used to allocate experimental groups. Sample size and standard deviation were based on empirical data from pilot experiments. All procedures were performed in accordance with the approved protocols using IACUC guidelines of the California Institute of Technology.

Construction of chromosomal library and screen

Genomic DNA was isolated from overnight culture of *B. fragilis* using a commercial kit (Wizard® Genomic DNA Purification Kit, Promega). 20 µg of genomic DNA was incubated with 4U of Sau3AI for 5, 10, 15, or 20 minutes at 37°C in 50 µl volume and the partially digested genomic DNA was separated by electrophoresis on 0.7% agarose gel. 9-10 kb fragment DNA was excised and recovered from the agarose gel (Zymoclean™ Gel DNA Recovery Kit, Zymo Research). Insert DNA was ligated to *Bgl*III site of plasmid vector (pFD340-*cat*BII, Supplementary Table 1), transformed into *E. coli* and amplified on LB-ampicillin plate. Individual clones from the plasmid library were mobilized from *E. coli* to *B. vulgatus* by conjugal helper plasmid RK231 generating a library of *B. vulgatus* hosting *B. fragilis* chromosomal DNA fragments consisting of approximately ~2100 clones. To screen the library *in vivo*, pools of 96 clones (10⁶ CFU of each clone) were gavaged into 22 germ-free Swiss Webster mice (10⁸ CFU per animal) pre-colonized with *B. vulgatus* pFD340 for 1-2 weeks. Two weeks after gavage, fresh fecal samples were plated on BHIS agar plate containing chloramphenicol to select for clones with colonization phenotype.

Generation of *ccfA*, *ccfC*, *ccfD*, *ccfE*, *ccfC-E* (Δ CCF) and Δ BF0227-0229 deletion mutants

~2 kb DNA segments flanking the region to be deleted were PCR amplified using primers listed in Supplementary Table 2. Reverse primer of the left flanking DNA and forward primer of the right flanking DNA were designed to be partially complementary at their 5' ends by 18-21 bp. Fusion PCR was performed using the left and right flanking DNA (~300 ng each after gel purification) as DNA template and forward primer of the left flanking DNA and reverse primer of the right flanking DNA²⁷. The fused PCR product was cloned into *Bam*HI or *Sal*I site of the *Bacteroides* conjugal suicide vector pNJR6 and mobilized into *B. fragilis*. Colonies selected for erythromycin resistance (Em^r), indicating integration of the suicide vector into the host chromosome were passaged for five days and then plated on nonselective medium (BHIS). The resulting colonies were replica plated to BHIS containing Em, and Em^s (erythromycin sensitive) colonies were screened by PCR to distinguish wild-type revertants from strains with the desired mutation. The same strategy was employed to generate Δ *ccfC-E* deletion mutant from *B. vulgatus*.

Quantitative RT-PCR (qRT-PCR)

Total RNA was extracted from mid-log phase bacterial culture using ZR Fungal/Bacterial RNA MiniPrep™ (Zymo Research), feces and cecal content from mice using ZR Soil/Fecal RNA MicroPrep™ (Zymo Research), and mouse colon tissues after removing luminal content by gently scraping the mucosal surface and PBS rinse using Trizol (Invitrogen). cDNA was made using an iSCRIPT cDNA synthesis kit per manufacturer's instructions (Bio-Rad). All qRT-PCR reactions were performed in ABI PRISM 7900HT Fast Real-Time

PCR System (Applied Biosystems) using Power SYBR Green PCR Master Mix (Applied Biosystems). Gene-specific primers are described in Supplementary Table 2.

Immunofluorescent staining of colon whole-mounts and frozen sections

For whole-mount staining, colons were fixed in buffered 4% paraformaldehyde, washed with PBS and subjected to indirect immunofluorescence. Tissues were made permeable by incubation with 0.5% (wt/vol) saponin, 2% (vol/vol) FBS, and 0.09% (wt/vol) azide in PBS for at least 18 hours. The same buffer was used for subsequent incubations with antibodies. Colon fragments were incubated with a primary polyclonal chicken IgY anti-*B. fragilis* antibodies for 12-16 hours at room temperature (RT) followed by 1-2 hour incubation at 37°C. Following PBS washes, samples were reacted with goat anti-chicken IgY secondary antibodies (Alexa Fluor 488 or Alexa Fluor 633, 2 µg/ml, Molecular Probes), fluorescently labeled phalloidin (fluorescein or AF568, 2 U/ml, Molecular Probes) and DAPI (2 µg/ml, Molecular Probes) for 1 hour at RT. Tissues were mounted in Prolong Gold (Invitrogen) and allowed to cure for at least 48 hours prior to imaging. In some experiments, anti-*B. fragilis* antibodies were pre-absorbed on tissue fragments derived from either germ-free mice (up to 18 hours at RT) or SPF mice (1 hour at RT).

For frozen sections, colon tissues were embedded in O.C.T. Compound (Sakura Finetek), frozen on dry ice, and stored at -80°C. Frozen blocks were cut with a thickness of 10 µm using a Microm HM505E cryostat, and sections were collected on positively charged slides (Fisher Scientific) for staining. Slides were fixed with 4% buffered paraformaldehyde for 10 minutes and washed 2×10 minutes with PBS. Tissue sections were blocked with 10% normal goat serum and 0.5% bovine serum albumin in PBS for 1 hour at RT. Sections were incubated with anti-*B. fragilis* antibodies for at least 8 hours at 4°C, washed 2 times for 10 minutes with PBS, reacted with secondary reagents and mounted as described above. In some experiments, anti-*B. fragilis* antibodies were pre-absorbed for 1 hour at RT on tissue sections derived from germ-free mice.

Fluorescence microscopy

An SP5 resonant laser-scanning confocal and two-photon microscope (both scanning heads mounted on the same DM 6000 upright microscope, Leica Microsystems) with a 40× oil objective (numerical aperture 1.4) or 63× oil objective (numerical aperture 1.4) were used for fluorescence microscopy. Images used for 3D reconstructions were acquired using dual confocal – two-photon mode. For confocal imaging, 488-nm and 543-nm excitation wavelengths were used for Alexa Fluor 488-labeled bacteria and Alexa Fluor 568-labeled phalloidin, and signals were detected with internal photomultiplier tubes. 2-photon imaging was performed with 4 nondescanned detectors (Leica Microsystems) and a Chameleon Ultra Ti: Sapphire laser (Coherent) tuned at 700–800 nm for acquisition. Emitted fluorescence was split with 3 dichroic mirrors (496 nm, 560 nm and 593 nm) and passed through an emission filter (Semrock) at 585/40 nm. Images (512×512) acquired with a 0.5 µm Z step were smoothed by median filtering at kernel size 3 × 3 pixels. 3D reconstructions of crypts and bacteria were performed using Imaris software (version 7.5.1 ×64; Bitplane AG). Crypt structures were visualized by DAPI and phalloidin signals. Images used for quantification were acquired with FluoView FV10i confocal microscope (Olympus) using 60× (numerical aperture 1.35) oil objective.

Image analysis

For bacterial localization with respect to the epithelial layer, frames of 512×512 pixels were acquired with 1 µm Z steps in the crypt length axis. Images were processed using ImageJ software (NIH). Background was subtracted (rolling ball method), images were smoothed by median filtering (3×3 pixels), segmented by threshold and position of the signal in the Z

stack was recorded. Data did not follow normal distribution and were analyzed by non-parametric two-sided Mann-Whitney U test.

For quantification of crypt associated bacterial signals from antibiotic treated animals, stacks of 512×512 pixels by 8 frames (1 μm per frame) were flattened by maximum intensity projection and filtered by median (3×3 kernel size). Images were segmented by thresholding. Number of positive spots/1000 μm² and area occupied by individual spots were analyzed. Data were not normally distributed and were analyzed by Mann-Whitney or Kruskal-Wallis followed by Dunn's multiple comparisons test where appropriate. 11-13 stacks/group were examined. Total area that was analyzed within the group of stacks was between 0.08-0.2 mm².

Gnotobiotic animal colonization experiments

8-12 week old germ-free Swiss Webster mice were gavaged once with a 100 μl of bacterial suspension for mono-association (~10⁸ CFU of each bacterial strain harvested from a log-phase culture and resuspended in PBS with 1.5% NaHCO₃). For sequential colonization, germ-free mice were mono-associated with an initial strain for 6-7 days and subsequently gavaged with a 100 μl suspension of a challenge strain. All *Bacteroides* strains used to colonize germ-free animals were resistant to gentamicin inherently, and to erythromycin by plasmid. Unless otherwise indicated, the initial strains carried pFD340-*cat* (chloramphenicol resistant; Cm^r) and the challenge strains, pFD340-*tetQ* (tetracycline resistant; Tet^r). For horizontal transfer by encounter experiment, two single-housed mice that were mono-associated with either WT *B. fragilis* pFD340-*tetQ* or *B. fragilis*ΔCCF pFD340-*cat* for at least 3 weeks were co-housed in a fresh sterile cage for 4 hours and then separated. At each time point, fresh fecal samples were collected, weighed, homogenized and serially diluted in PBS (or BHI broth) for plating on selective media to determine bacterial CFU per g of feces.

SPF animal colonization experiments

7-8 week old male SPF mice (C57BL/6, Swiss Webster, NOD, and Rag^{-/-}) were given a single inoculum of 1×10⁸ CFU of either WT *B. fragilis*, *B. fragilis*ΔCCF, or 1:1 mixture of the two strains by oral gavage. At each time point, bacterial genomic DNA from fecal samples were isolated using a commercial kit (ZR Fecal DNA MiniPrep™, Zymo Research) following the manufacturer's instructions and the relative densities of bacteria were determined by qPCR using strain-specific primers (Supplementary Table 2).

Citrobacter rodentium infection

8 week old female SPF Swiss Webster mice were treated with metronidazole (100 mg/kg) by oral gavage every 24 hours and ciprofloxacin dissolved in drinking water (0.625 mg/ml; Hikma Pharmaceuticals) for seven days; mice were transferred to a fresh sterile cage every two days. Two days after the cessation of antibiotic treatment, mice were orally gavaged with a single inoculum of 1:1 mixture of WT *B. fragilis* and *B. fragilis*ΔCCF (~5×10⁸ CFU total per animal). 6-7 days after *B. fragilis* gavage, mice were either infected orally with ~5×10⁸ CFU of overnight culture *C. rodentium* or PBS-gavaged as control. The relative densities of bacteria were determined by fecal bacterial DNA extraction and qPCR.

Antibiotic treatment

8 week old female SPF Swiss Webster mice were treated with metronidazole (100 mg/kg) by oral gavage every 24 hours and ciprofloxacin dissolved in drinking water (0.625 mg/ml) for seven days; mice were transferred to a fresh sterile cage every two days. Two days after the cessation of antibiotic treatment, mice were orally gavaged with a single inoculum of 1:1 mixture of WT *B. fragilis* and *B. fragilis*ΔCCF (~5×10⁸ CFU total per animal). 6-7 days

after *B. fragilis* gavage, one group of mice were treated with ciprofloxacin for 4 days dissolved in drinking water (1 mg/ml) and another group were left untreated. The relative densities of bacteria were determined by fecal bacterial DNA extraction and qPCR.

Antibiotic treatment for colon whole-mount imaging

8 week old female SPF Swiss Webster mice were treated with metronidazole (100 mg/kg) by oral gavage every 24 hours and ciprofloxacin dissolved in drinking water (0.625 mg/ml) for seven days; mice were transferred to a fresh sterile cage every two days. Two days after the cessation of antibiotic treatment, mice were orally gavaged with a 100 μ l inoculum of *B. fragilis* ($\sim 10^8$ CFU) or PBS. 7 days after bacterial gavage (day 16), PBS or *B. fragilis* inoculated mice were treated with ciprofloxacin in drinking water (1 mg/ml) for 7 days and one group of *B. fragilis* inoculated mice were left untreated. At the end of the ciprofloxacin treatment (day 23), feces were collected for stool DNA extraction and colon tissues were harvested and fixed with 4% PFA for whole-mount imaging.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Taren Thron and Sara McBride (Caltech) for the maintenance of germ-free animals, Jane Selicha (Caltech) for assisting with the experimental procedures, and Grzegorz Chodaczek (LIAI) for help with confocal and two-photon microscopy. We are grateful to Dr. Eric C. Martens (Univ. of Michigan) and members of the Mazmanian laboratory for critical review of the manuscript. S.M.L. and G.P.D. were supported by a pre-doctoral training grant (GM007616). This work was supported by grants from the NIH (GM099535 and DK078938) and the Crohn's and Colitis Foundation of America to S.K.M.

References

1. McFall-Ngai M, et al. Animals in a bacterial world, a new imperative for the life sciences. *Proceedings of the National Academy of Sciences of the United States of America*. 2013; 110:3229–3236. 10.1073/pnas.1218525110. [PubMed: 23391737]
2. Structure, function and diversity of the healthy human microbiome. *Nature*. 2012; 486:207–214. 10.1038/nature11234. [PubMed: 22699609]
3. Yatsunenkov T, et al. Human gut microbiome viewed across age and geography. *Nature*. 2012; 486:222–227. 10.1038/nature11053. [PubMed: 22699611]
4. Qin J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. *Nature*. 2010; 464:59–65. nature08821 [pii] 10.1038/nature08821. [PubMed: 20203603]
5. Palmer C, Bik EM, DiGiulio DB, Relman DA, Brown PO. Development of the Human Infant Intestinal Microbiota. *PLoS Biol*. 2007; 5:e177. [PubMed: 17594176]
6. Dethlefsen L, Huse S, Sogin ML, Relman DA. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. *PLoS Biol*. 2008; 6:e280. 10.1371/journal.pbio.0060280. [PubMed: 19018661]
7. Eckburg PB, et al. Diversity of the human intestinal microbial flora. *Science*. 2005; 308:1635–1638. [PubMed: 15831718]
8. Bry L, Falk PG, Midtvedt T, Gordon JI. A model of host-microbial interactions in an open mammalian ecosystem. *Science*. 1996; 273:1380–1383. [PubMed: 8703071]
9. Xu J, et al. A genomic view of the human-Bacteroides thetaiotaomicron symbiosis. *Science*. 2003; 299:2074–2076. [PubMed: 12663928]
10. Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. *Cell*. 2005; 122:107–118. [PubMed: 16009137]

11. Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal inflammatory disease. *Nature*. 2008; 453:620–625. nature07008 [pii] 10.1038/nature07008. [PubMed: 18509436]
12. Round JL, Mazmanian SK. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. *Proc Natl Acad Sci U S A*. 2010; 107:12204–12209. 0909122107 [pii] 10.1073/pnas.0909122107. [PubMed: 20566854]
13. Ochoa-Reparaz J, et al. Central nervous system demyelinating disease protection by the human commensal *Bacteroides fragilis* depends on polysaccharide A expression. *J Immunol*. 2010; 185:4101–4108. jimmunol.1001443 [pii] 10.4049/jimmunol.1001443. [PubMed: 20817872]
14. Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. *Cell*. 2006; 124:837–848. [PubMed: 16497592]
15. Koropatkin NM, Cameron EA, Martens EC. How glycan metabolism shapes the human gut microbiota. *Nat Rev Microbiol*. 2012; 10:323–335. nrmicro2746 [pii] 10.1038/nrmicro2746. [PubMed: 22491358]
16. Martens EC, Koropatkin NM, Smith TJ, Gordon JI. Complex glycan catabolism by the human gut microbiota: the Bacteroidetes Sus-like paradigm. *J Biol Chem*. 2009; 284:24673–24677. R109.022848 [pii] 10.1074/jbc.R109.022848. [PubMed: 19553672]
17. Shipman JA, Berleman JE, Salyers AA. Characterization of four outer membrane proteins involved in binding starch to the cell surface of *Bacteroides thetaiotaomicron*. *J Bacteriol*. 2000; 182:5365–5372. [PubMed: 10986238]
18. Schauer K, Rodionov DA, de Reuse H. New substrates for TonB-dependent transport: do we only see the ‘tip of the iceberg’? *Trends Biochem Sci*. 2008; 33:330–338. S0968-0004(08)00101-1 [pii] 10.1016/j.tibs.2008.04.012. [PubMed: 18539464]
19. Kawada M, et al. Chitinase 3-like-1 enhances bacterial adhesion to colonic epithelial cells through the interaction with bacterial chitin-binding protein. *Lab Invest*. 2008; 88:883–895. labinvest200847 [pii] 10.1038/labinvest.2008.47. [PubMed: 18490894]
20. Martens EC, Chiang HC, Gordon JI. Mucosal glycan foraging enhances fitness and transmission of a saccharolytic human gut bacterial symbiont. *Cell Host Microbe*. 2008; 4:447–457. S1931-3128(08)00303-X [pii] 10.1016/j.chom.2008.09.007. [PubMed: 18996345]
21. Sonnenburg JL, et al. Glycan foraging in vivo by an intestine-adapted bacterial symbiont. *Science*. 2005; 307:1955–1959. [PubMed: 15790854]
22. Round JL, et al. The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. *Science*. 2011; 332:974–977. 10.1126/science.1206095. [PubMed: 21512004]
23. Pedron T, et al. A crypt-specific core microbiota resides in the mouse colon. *MBio*. 2012; 3:mBio.00116-12 [pii] 10.1128/mBio.00116-12.
24. Mundy R, MacDonald TT, Dougan G, Frankel G, Wiles S. *Citrobacter rodentium* of mice and man. *Cellular microbiology*. 2005; 7:1697–1706. 10.1111/j.1462-5822.2005.00625.x. [PubMed: 16309456]
25. Bloom SM, et al. Commensal *Bacteroides* species induce colitis in host-genotype-specific fashion in a mouse model of inflammatory bowel disease. *Cell Host Microbe*. 2011; 9:390–403. S1931-3128(11)00131-4 [pii] 10.1016/j.chom.2011.04.009. [PubMed: 21575910]
26. Freter R, Brickner H, Botney M, Cleven D, Aranki A. Mechanisms that control bacterial populations in continuous-flow culture models of mouse large intestinal flora. *Infection and immunity*. 1983; 39:676–685. [PubMed: 6339388]
27. Wurch T, Lestienne F, Pauwels PJ. A modified overlap extension PCR method to create chimeric genes in the absence of restriction enzymes. *Biotechnol Tech*. 1998; 12:653–657.




Figure 1. *Bacteroides* species occupy species-specific niches in the gut via an evolutionarily conserved genetic locus

a-c, Germ-free mice were mono-associated with *B. fragilis* and challenged orally with (a) *B. theta* *taioamicron*; (b) *B. vulgatus*; or (c) *B. fragilis*. **d**, Mice were mono-associated with erythromycin sensitive *B. fragilis*, and subsequently challenged with erythromycin resistant *B. fragilis*. Erythromycin was administered where indicated. **e**, Genomic organization of the *ccf* locus. **f**, Mice were mono-associated with either WT *B. fragilis*, mutant strains deleted in *ccfC*, *ccfD*, *ccfE* and *ccfC-E* (BF Δ CCF), or complemented strain (BF Δ CCF:CCF) and challenged with WT *B. fragilis*. CFUs were determined after 30 days. **g**, Mice were mono-associated with WT *B. vulgatus* or a mutant strain deleted in *ccfC-E* genes (BV Δ CCF), and challenged with WT *B. vulgatus*. CFUs were determined after 30 days. In all sequential colonization studies, results are representative of at least 2 independent trials (n=3-4 animals/group). **h**, Cross-colonization between WT *B. fragilis* and BF Δ CCF mono-associated mice at 7 days after encounter measured by CFUs of the initially colonizing and the horizontally transmitted (challenge) strains. (n=2 animals/encounter, 5 independent trials). All graphs: Dashed line indicates the limit of detection at 100 CFU/g feces, and error bars indicate standard deviation (SD).




Figure 2. *B. fragilis* colonization of the colonic crypts is mediated by the CCF system
a, qRT-PCR of *ccf* gene expression levels normalized to 16S rRNA (n=3 animals, 2 trials).
b, Mice were mono-associated with either WT *B. fragilis* or *B. fragilis*ΔCCF, and challenged with WT *B. fragilis*. The percentage of challenge strain was determined in the lumen (feces) and colon after 1 day (n=8 animals/group). **c**, Confocal micrographs of germ-free, WT *B. fragilis* or *B. fragilis*ΔCCF mono-associated mice colon whole-mount. Crypts are visualized by DAPI (nuclei, blue) and phalloidin (F-actin, green). Bacteria (red) are stained with IgY polyclonal antibody raised against *B. fragilis*. Images are representative of 7 different sites analyzed from at least 2 different colons. Scale bar: 5 μm. **d**, 3D reconstructions of colon crypts from WT *B. fragilis* or *B. fragilis*ΔCCF mono-associated mice. Bacteria are detected on the apical surface of the epithelium (arrows) and in the crypt space (arrowhead). Scale bar: 10 μm. **e**, Quantification of bacterial penetration, measured as distance from the epithelial surface per crypt. Error bars indicate standard error of the mean (SEM). NS: not significant. ND: not detected. ** $p < 0.01$. **** $p < 0.0001$.




Figure 3. *B. fragilis* requires the *ccf* genes for stable and resilient colonization of mice
a, Groups of SPF *Rag*^{-/-} mice were gavaged with either WT *B. fragilis* or *B. fragilis*ΔCCF.
b, SPF *Rag*^{-/-} mice were given a 1:1 co-inoculum of WT *B. fragilis* and *B. fragilis*ΔCCF by single gavage. **c**, SPF NOD mice were gavaged with either WT *B. fragilis* or *B. fragilis*ΔCCF. **d**, SPF NOD mice were given a 1:1 co-inoculum of WT *B. fragilis* and *B. fragilis*ΔCCF by single gavage. **e**, SPF mice were co-associated with WT *B. fragilis* and *B. fragilis*ΔCCF, and infected with *Citrobacter rodentium*. **f**, SPF mice were co-associated with WT *B. fragilis* and *B. fragilis*ΔCCF, and given ciprofloxacin in drinking water for the time period shown. For all analyses, bacterial colonization levels were assessed by real-time qRT-PCR from stool DNA (n=4 animals/group). Results are representative of at least 2 independent trials per experiments. Error bars indicate SEM. **p*<0.05. ****p*<0.001.